上海医药(601607.SH):不超11.5亿元取得T3011(瘤内注射)项目在大中华地区商业化的独家权益
格隆汇 8 月 6日丨上海医药(601607.SH)公布,2020年8月6日,公司与深圳市亦诺微医药科技有限公司(“亦诺微”)签订《授权许可协议》,将出资不超过人民币11.5亿元取得T3011(瘤内注射)项目在大中华地区(中国大陆、香港、澳门以及台湾)商业化的独家权益。
T3011是新一代的溶瘤HSV病毒产品,采用了专有的病毒骨架并且插入了独特的细胞因子组合(IL-12和PD-1抗体),在兼顾安全性的同时提高了病毒的杀伤力,进一步强化了免疫协同抗肿瘤作用。
溶瘤病毒是一种病毒特异性感染并杀伤肿瘤细胞的新型肿瘤疗法,通过直接裂解肿瘤细胞激发机体系统性的抗肿瘤免疫反应。从作用机理来看,溶瘤病毒具有与化疗、放疗、靶向药物、免疫治疗等多种肿瘤疗法协同联用增效的潜力,并且可作为一种基因递送的载体工具。
T3011(瘤内注射)项目的国内IND申请已于2019年8月获批,正在上海复旦大学肿瘤医院等机构开展针对实体瘤适应症的I期临床试验,目前已入组患者。同时,T3011(瘤内注射)项目的美国IND已于2020年5月获得美国FDA批准。
目前,全球已经上市的溶瘤病毒产品包括美国Amgen公司的T-VEC和上海三维生物技术有限公司的安柯瑞。根据Evaluate Pharma数据库,2019年溶瘤病毒产品全球销售额为0.68亿美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.